Highlights from the 2019 European Congress on Treatment and Research in Multiple Sclerosis (ECTRIMS 2019)

Jan D Lünemann1, Judit Diaz-Diaz2, Bruno Stankoff3

  • 1Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|May 5, 2020
PubMed

Insights

The 2019 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress showcased significant advancements in multiple sclerosis (MS) research. This report highlights key findings from basic, translational, and clinical studies presented.

Area of Science:

  • Neurology
  • Immunology
  • Clinical Research

Background:

  • The 2019 ECTRIMS Congress in Stockholm saw record attendance and scientific submissions.
  • Multiple sclerosis (MS) research is rapidly evolving, necessitating a review of recent findings.

Purpose of the Study:

  • To identify and highlight novel, high-quality basic and clinical research in multiple sclerosis presented at the 2019 ECTRIMS Congress.
  • To provide a curated selection of outstanding studies for the scientific community.

Main Methods:

  • Systematic assessment of abstracts from all poster and oral presentations at the 2019 ECTRIMS Congress.
  • Selection based on novelty, scientific quality, and relevance to basic and clinical MS research.
  • Inclusion of additional literature references for enhanced understanding.

Main Results:

  • A record number of participants (9361) and abstracts (1541) were presented, indicating a vibrant research landscape.
  • The report focuses on a diverse range of studies, encompassing basic science, translational research, and clinical trials.
  • Selected abstracts represent significant contributions to the understanding and treatment of MS.

Conclusions:

  • The 2019 ECTRIMS Congress served as a crucial platform for disseminating cutting-edge multiple sclerosis research.
  • The highlighted studies offer valuable insights and potential future directions for MS diagnosis, treatment, and management.
  • Access to presented research is available through the ECTRIMS online library and journal publications.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.6K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
852
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.2K